These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 9627539

  • 1. Advances in drug treatment of dyslipidemia: focus on atorvastatin.
    Davignon J.
    Can J Cardiol; 1998 May; 14 Suppl B():28B-38B. PubMed ID: 9627539
    [Abstract] [Full Text] [Related]

  • 2. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
    Leibovitz E, Harats D, Gavish D.
    Isr Med Assoc J; 2002 Jun; 4(6):407-10. PubMed ID: 12073409
    [Abstract] [Full Text] [Related]

  • 4. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Jun; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 5. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV, Yegorova YV.
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [Abstract] [Full Text] [Related]

  • 6. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 7. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [Abstract] [Full Text] [Related]

  • 8. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 9. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 10. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    Wanner C, Krane V.
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
    [Abstract] [Full Text] [Related]

  • 11. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, Abramowicz D.
    Transplantation; 2006 Sep 27; 82(6):771-8. PubMed ID: 17006324
    [Abstract] [Full Text] [Related]

  • 12. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK.
    Am J Manag Care; 2002 Sep 27; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [Abstract] [Full Text] [Related]

  • 13. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 27; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 14. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec 10; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 16. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 10; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 17. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 10; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Nov 10; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 19. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 10; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC.
    Am Heart J; 2009 Feb 10; 157(2):352-360.e2. PubMed ID: 19185645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.